Difference between revisions of "Wilms tumor"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Wilms' tumor regimens" to "Category:Wilms tumor regimens") |
Warner-admin (talk | contribs) |
||
Line 81: | Line 81: | ||
|} | |} | ||
===Regimen {{#subobject:a67321|Variant=1}}=== | ===Regimen {{#subobject:a67321|Variant=1}}=== | ||
− | {| class="wikitable" style="width: | + | {| class="wikitable" style="width: 50%; text-align:center;" |
− | !style="width: | + | !style="width: 25%"|Study |
− | !style="width: | + | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] |
|- | |- | ||
|[https://jamanetwork.com/journals/jama/article-abstract/335953 Sullivan et al. 1967] | |[https://jamanetwork.com/journals/jama/article-abstract/335953 Sullivan et al. 1967] |
Revision as of 00:52, 10 May 2019
Section editor | |
---|---|
Wayne H. Liang, MD, MS UAB Birmingham, AL ![]() |
3 regimens on this page
3 variants on this page
|
All lines of therapy
Dactinomycin monotherapy
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Wolff et al. 1968 | Randomized (E) | Single course of dactinomycin | Seems to have superior RFS |
Preceding treatment
Chemotherapy
- Dactinomycin (Cosmegen) 15 mcg/kg IV once per day on days 1 to 5
6-week cycle for 3 cycles, then 3-month cycle for 4 cycles
References
- Wolff JA, Newton WA Jr, Krivit W, D'Angio GJ. Single versus multiple dose dactinomycin therapy of Wilms's tumor: a controlled co-operative study conducted by the Children's Cancer Study Group A (formerly Acute Leukemia Co-operative Chemotherapy Group A). N Engl J Med. 1968 Aug 8;279(6):290-4. link to original article PubMed
- Update: Wolff JA, D'Angio G, Hartmann J, Krivit W, Newton WA Jr. Long-term evaluation of single versus multiple courses of actinomycin D therapy of Wilms's tumor. N Engl J Med. 1974 Jan 10;290(2):84-6. link to original article contains verified protocol PubMed
Dactinomycin & Vincristine
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
de Kraker et al. 2004 (SIOP 93-01) | Phase III (E) | Prolonged chemotherapy | Equivalent EFS |
Pritchard-Jones et al. 2015 (SIOP WT 2001) | Phase III (E) | Dactinomycin, Doxorubicin, Vincristine | Non-inferior EFS |
Preceding treatment
Chemotherapy
References
- SIOP 93-01: de Kraker J, Graf N, van Tinteren H, Pein F, Sandstedt B, Godzinski J, Tournade MF; SIOP. Reduction of postoperative chemotherapy in children with stage I intermediate-risk and anaplastic Wilms' tumour (SIOP 93-01 trial): a randomised controlled trial. Lancet. 2004 Oct 2-8;364(9441):1229-35. link to original article PubMed
- SIOP WT 2001: Pritchard-Jones K, Bergeron C, de Camargo B, van den Heuvel-Eibrink MM, Acha T, Godzinski J, Oldenburger F, Boccon-Gibod L, Leuschner I, Vujanic G, Sandstedt B, de Kraker J, van Tinteren H, Graf N; SIOP Renal Tumours Study Group. Omission of doxorubicin from the treatment of stage II-III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial. Lancet. 2015 Sep 19;386(9999):1156-64. Epub 2015 Jul 9. link to original article PubMed
Vincristine monotherapy
back to top |
Regimen
Study | Evidence |
---|---|
Sullivan et al. 1967 | Pilot |
Chemotherapy
Subsequent treatment
References
- Sullivan MP, Sutow WW, Cangir A, Taylor G. Vincristine sulfate in management of Wilms' tumor: replacement of preoperative irradiation by chemotherapy. JAMA. 1967 Oct 30;202(5):381-4. link to original article PubMed